Latest From DiaSorin SPA
Sanofi signed a $2bn deal with DiCE Molecules to develop small molecules against targets previously addressed by biologics; Toshiba sold its diagnostics and medical imaging division to Canon for $6bn. Debt offerings dominated biopharma and device financings.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced March-April 2016.
Emerging Irish IVD company HiberGene Diagnostics has just CE marked HG Meningococcus, a molecular diagnostic test for bacterial meningitis that can detect Neisseria meningitidis in cerebrospinal fluid, whole blood and via a nasopharyngeal swab in less than one hour. The company is set to launch the test in Europe with distribution agreements in place for Ireland, Germany, Austria, Spain, Turkey and Poland.
Dublin-based start-up HiberGene Diagnostics Ltd. aims to create rapid, accurate, and simple diagnostic tests for infectious diseases based on LAMP (loop-mediated isothermal amplification) technology, which uses nucleic acid amplification to identify target genes.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- DiaSorin SPA
- Senior Management
Carlo Rosa, CEO
Piergiorgio Pedron, SVP, CFO
Chen Even, Chief Commercial Officer
- Contact Info
Phone: (39) 0161 487 526
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.